The AKAP13 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the A-kinase anchoring protein 13 (AKAP13) gene has been disrupted in the HEK293T human embryonic kidney cell background. This polyclonal knockout pool provides a heterogeneous loss-of-function model suitable for studying AKAP13-dependent signaling without clonal selection artifacts. The product is designed for researchers investigating the scaffolding functions of AKAP13 in the context of Rho GTPase and cAMP-dependent pathways.
HEK293T cells are a widely utilized human embryonic kidney cell line stably expressing the SV40 large T antigen, which enables high-level episomal replication of plasmids containing the SV40 origin of replication. These cells are characterized by their robust protein expression capabilities, efficient viral transduction, and ease of culture, making them a preferred host for signal transduction studies, functional genomics, and drug discovery applications. The SV40 T antigen allows for amplified expression of transfected genes and enhances recombinant protein production, facilitating downstream biochemical and cell-based assays.
AKAP13 (also known as Lbc or Brx) functions as a scaffold protein that tethers protein kinase A (PKA) to specific subcellular compartments and physically links PKA to RhoA signaling. Upon stimulation by upstream GPCR agonists such as lysophosphatidic acid (LPA) and thrombin, or by cAMP elevation, AKAP13 facilitates the activation of RhoA through its intrinsic RhoGEF domain. This coupling mechanism promotes GDP/GTP exchange on RhoA and subsequent downstream effects on actin cytoskeleton dynamics and serum response factor (SRF)-mediated gene transcription. AKAP13 interacts with key signaling components, including PKA regulatory subunits, 14-3-3 proteins, and heterotrimeric G proteins G??12/13, integrating cAMP and RhoA pathways to regulate cellular processes like proliferation, migration, and hypertrophy.
In the HEK293T background, loss of AKAP13 disrupts the coordinated regulation of PKA-RhoA crosstalk, providing a tool to dissect how scaffolding proteins direct signaling specificity. This model is particularly relevant for exploring the molecular underpinnings of diseases such as cancer, where AKAP13-mediated RhoA activation contributes to tumor cell invasion, and cardiac hypertrophy, where AKAP13 drives pathological remodeling. The HEK293T system??s tractability allows for the co-expression of mutant forms or biosensors, enabling detailed structure-function analyses of AKAP13??s scaffolding and GEF activities.
Researchers can employ this polyclonal knockout population in a variety of assays to investigate signal transduction mechanisms. Western blotting and RT-qPCR can be used to assess changes in downstream targets such as SRF-dependent transcripts, while immunofluorescence enables visualization of altered actin organization or subcellular localization of PKA. RhoA activation assays (e.g., GST-RBD pull-down) directly measure the impact of AKAP13 disruption on RhoA GTP loading, and SRF reporter gene assays provide a functional readout for transcriptional outcomes. This model supports functional genomics studies aimed at deconvoluting AKAP13??s role in GPCR-cAMP-PKA-RhoA networks and serves as a platform for drug target validation where inhibitors of RhoGEF activity are being investigated. For additional information, please contact Ascent Research.
